Indexed keywords
BEVACIZUMAB;
DEXAMETHASONE;
RANIBIZUMAB;
ANTERIOR EYE SEGMENT;
BLINDNESS;
CLINICAL TRIAL;
CORNEA NEOVASCULARIZATION;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG EFFICACY;
DRUG SAFETY;
EDITORIAL;
HUMAN;
INTRAOCULAR PRESSURE;
LASER COAGULATION;
NONHUMAN;
RETINA MACULA AGE RELATED DEGENERATION;
TREATMENT RESPONSE;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTERIOR EYE SEGMENT;
ANTIBODIES, MONOCLONAL;
CORNEA;
COST-BENEFIT ANALYSIS;
EYE;
HUMANS;
MACULAR DEGENERATION;
NEOVASCULARIZATION, PATHOLOGIC;
OPHTHALMOLOGY;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
1
23044505200
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005, 36:331-5.
(2005)
Ophthalmic Surg Lasers Imaging , vol.36
, pp. 331-335
Rosenfeld, P.J.1
Moshfeghi, A.A.2
Puliafito, C.A.3
2
77954630527
Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin®) in neovascular glaucoma
Ghosh S, Singh D, Ruddle JB, Shiu M, Coote MA, Crowston JG. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin®) in neovascular glaucoma. Clin Experiment Ophthalmol 2010, 38:353-7.
(2010)
Clin Experiment Ophthalmol , vol.38
, pp. 353-357
Ghosh, S.1
Singh, D.2
Ruddle, J.B.3
Shiu, M.4
Coote, M.A.5
Crowston, J.G.6
3
77954630190
Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone
Hoffart L, Matonti F, Conrath J. Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone. Clin Experiment Ophthalmol 2010, 38:346-52.
(2010)
Clin Experiment Ophthalmol , vol.38
, pp. 346-352
Hoffart, L.1
Matonti, F.2
Conrath, J.3
et al4
4
65249103986
Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study
Dastjerdi MH, Al-Arfaj KM, Nallasamy N. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009, 127:381-9.
(2009)
Arch Ophthalmol , vol.127
, pp. 381-389
Dastjerdi, M.H.1
Al-Arfaj, K.M.2
Nallasamy, N.3
et al4
5
44449119809
The effect of topical bevacizumab on corneal neovascularization
Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008, 115:e33-e38.
(2008)
Ophthalmology , vol.115
Kim, S.W.1
Ha, B.J.2
Kim, E.K.3
Tchah, H.4
Kim, T.I.5
6
73649130636
Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium
Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 2010, 35:17-22.
(2010)
Curr Eye Res , vol.35
, pp. 17-22
Fallah, M.R.1
Khosravi, K.2
Hashemian, M.N.3
Beheshtnezhad, A.H.4
Rajabi, M.T.5
Gohari, M.6
7
33846973644
Ranibizumab for neovascular age-related macular degeneration
Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007, 356:748-9.
(2007)
N Engl J Med , vol.356
, pp. 748-749
Gillies, M.C.1
Wong, T.Y.2
